R.PR
REGISTERED-PRINCIPAL REGISTER
09/07/2021
Back to search
Official data from USPTO
KYMAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
KYMAB
ST13
US500000088441516Class
5, 42, 44
Filing
88441516
Registration
6473731
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
04/29/2022
Trademark type
Word
Nice classes
5, 42, 44
Filing date
05/22/2019
Registration date
09/07/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/07/2021
Last transaction
04/29/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Cambridge, GB
Examiner
MANGUBAT, ALEXANDER
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Kymab Limited
Representatives
Mark H. Tidman BAKER & HOSTETLER LLP
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medical preparations containing monoclonal antibodies for the treatment and prophylaxis of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; Veterinary preparations containing monoclonal antibodies for treatment and prophylaxis of medical conditions in humanscancerinflammatoryautoimmune and infectious diseasesmedical diagnostics; sanitary preparations containing monoclonal antibodies for medical purposes; dietetic food and beverages containing monoclonal antibodiesfor medical and veterinary use; dietary supplements containing monoclonal antibodies for human beings and animals; dietary supplements containing monoclonal antibodies; Pharmaceutical preparations containing monoclonal antibodies for the treatment of treatment and prophylaxis of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseases and in the field of antibodies and immuno-oncology
Class 42
Scientificmedical and technological servicesscientific researchanalysis and testing in the field of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncologyscientific researchanalysis and testing in the field of antibodies and cell repertoires and researchdevelopment and design in the field of sciencemedicinetechnology; industrial analysis and industrial research servicestestinganalysisevaluation of the goods of others to assure compliance with industry standards; design and development of computer hardware and software; design and development of hardware and software for analysis and testing in the field of antibodies and biological cells and genetic discovery and clinical development; Clinical research in the field of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodiesimmuno-oncologyinflammationhaematology and infectious disease; Conducting clinical trials for others in the field of antibodiesmedical conditionscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; conducting clinical trials for pharmaceutical products for others in the field of medical conditionscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; scientific and medical screening and assaying of medical conditionscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnosticsin the field of antibodies and immuno-oncology; scientific and medical screening and assaying in the field of genetic discoveryclinical developmentantibodies and biological cells; chemical analysis; chemical research
Class 44
Medical services; diagnostic and prognostic medical services; veterinary services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; pharmaceutical consultation in the nature of pharmacy advice; medical and health services in the nature of the treatment and prophylaxis of medical conditions in humanscancerinflammatoryhematologyautoimmune and infectious diseasesmedical diagnostics; Medical screening
Publications
History of USPTO decisions and trademark events.
37 publications found
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
08/01/2021
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
04/21/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/23/2021
PUBO
PUBLISHED FOR OPPOSITION
03/23/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/03/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/17/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
02/17/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/17/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
02/17/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/17/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/09/2020
GNRT
NON-FINAL ACTION E-MAILED
10/09/2020
CNRT
NON-FINAL ACTION WRITTEN
10/09/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/22/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/21/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/21/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/16/2020
GNRT
NON-FINAL ACTION E-MAILED
03/16/2020
CNRT
NON-FINAL ACTION WRITTEN
03/16/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
03/09/2020
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
02/21/2020
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
02/21/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/14/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
02/14/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/14/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
02/14/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/14/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/29/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/28/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/28/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/09/2019
GNRT
NON-FINAL ACTION E-MAILED
08/09/2019
CNRT
NON-FINAL ACTION WRITTEN
08/09/2019
DOCK
ASSIGNED TO EXAMINER
08/09/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/06/2019
NWAP
NEW APPLICATION ENTERED
05/25/2019
Continuous trademark protection
Get notified about every new filing that threatens KYMAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.